Brokerages forecast that Beyondspring Inc (NASDAQ:BYSI) will post ($0.63) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Beyondspring’s earnings. Beyondspring reported earnings of ($0.61) per share during the same quarter last year, which would suggest a negative year over year growth rate of 3.3%. The business is expected to announce its next quarterly earnings results on Thursday, June 20th.
On average, analysts expect that Beyondspring will report full-year earnings of ($1.82) per share for the current fiscal year. For the next year, analysts expect that the business will report earnings of ($0.70) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Beyondspring.
Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter.
BYSI has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Beyondspring in a research note on Monday, March 4th. Maxim Group downgraded Beyondspring from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th.
Shares of NASDAQ:BYSI traded up $0.32 on Friday, reaching $15.01. The company had a trading volume of 100 shares, compared to its average volume of 9,573. Beyondspring has a 52-week low of $13.06 and a 52-week high of $30.98. The company has a market capitalization of $338.11 million, a PE ratio of -6.02 and a beta of 1.15.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
See Also: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.